Added to YB: 2025-06-24
Pitch date: 2025-04-11
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
-10.82%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Market Cap
$111.4B
Pitch Price
$487.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
19.79
P/E
28.64
EV/Sales
8.43
Sector
Biotechnology
Category
growth
Show full summary:
Hardman Johnston Large Cap Equity Strategy Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): Strong Q4'24 with revenue on target but higher OpEx to support pipeline. Confidence rising from consistent growth & portfolio expansion beyond cystic fibrosis. FDA approval of suzetrigine (VX-548) for moderate-to-severe acute pain offers new non-opioid treatment addressing major market need.
Read full article (1 min)